Compare · ABBV vs STTK
ABBV vs STTK
Side-by-side comparison of AbbVie Inc. (ABBV) and Shattuck Labs Inc. (STTK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and STTK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $449.63B, about 778.7x STTK ($577.4M).
- Over the past year, ABBV is up 34.5% and STTK is up 830.0% - STTK leads by 795.5 points.
- ABBV has been more active in the news (23 items in the past 4 weeks vs 4 for STTK).
- ABBV has more recent analyst coverage (25 ratings vs 13 for STTK).
- Company
- AbbVie Inc.
- Shattuck Labs Inc.
- Price
- $254.52+0.06%
- $7.53+6.66%
- Market cap
- $449.63B
- $577.4M
- 1M return
- +14.38%
- +73.50%
- 1Y return
- +34.48%
- +829.97%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2020
- News (4w)
- 23
- 4
- Recent ratings
- 25
- 13
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Shattuck Labs Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest STTK
- Amendment: SEC Form SCHEDULE 13D/A filed by Shattuck Labs Inc.
- Chief Technical Officer Shukla Abhinav A. exercised 12,563 shares at a strike of $3.57 and sold $2,874 worth of shares (410 units at $7.01) as part of a pre-agreed trading plan, increasing direct ownership by 14% to 98,533 units (SEC Form 4) to satisfy withholding obligation
- Chief Technical Officer Shukla Abhinav A. exercised 23,465 shares at a strike of $3.57 and sold $166,131 worth of shares (23,465 units at $7.08) as part of a pre-agreed trading plan (SEC Form 4) (for tax liability)
- Chief Medical Officer Pandite Arundathy N. sold $210,300 worth of shares (30,000 units at $7.01) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 136,219 units (SEC Form 4)
- SEC Form 4 filed by Director Ashiya Mona
- SEC Form 4 filed by Director Orbimed Advisors Llc
- Amendment: SEC Form SCHEDULE 13D/A filed by Shattuck Labs Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Shattuck Labs Inc.
- Director Siegall Clay B bought $250,000 worth of shares (62,500 units at $4.00), increasing direct ownership by 24% to 318,608 units (SEC Form 4)
- SEC Form 8-K filed by Shattuck Labs Inc.